Video
Dr. Gainor Discusses the Future of EGFR+ NSCLC
Author(s):
Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, attending physician, Massachusetts General Hospital, discusses the future of treatment for patients with EGFR-positive non-small cell lung cancer.
Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, attending physician, Massachusetts General Hospital, discusses the future of treatment for patients with EGFR-positive non-small cell lung cancer (NSCLC).
The results of FLAURA are convincing enough to suggest that osimertinib (Tagrisso) should be first-line treatment of choice for these patients, says Gainor.
Moving forward, better understanding response and resistance to osimertinib should be a priority, Gainor adds.
Related Videos
Related Content
